West Pharmaceutical(US:WST) GlobeNewswire News Room·2025-06-10 17:04Core Viewpoint - A class action securities lawsuit has been filed against West Pharmaceutical Services, Inc. alleging securities fraud that negatively impacted investors between February 16, 2023, and February 12, 2025 [1][2]. Summary by Sections Class Definition - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud during the specified period [2]. Case Details - The complaint alleges that West Pharmaceutical Services made false statements and concealed significant issues, including: - The company was experiencing ongoing destocking in its high-margin HVP portfolio, contrary to claims of strong visibility into customer demand [3]. - The SmartDose device, marketed as a high-margin growth product, was actually dilutive to profit margins due to operational inefficiencies [3]. - Margin pressures raised the risk of costly restructuring activities, including exiting continuous glucose monitoring contracts with long-term customers [3]. - Positive statements made by the defendants regarding the company's business and prospects were materially false or misleading [3]. Next Steps - Investors who suffered losses during the relevant timeframe have until July 7, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. Why Levi & Korsinsky - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders and consistently ranking among the top securities litigation firms in the U.S. [5].